Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway

Neural Regeneration Research

Volumn 8, Issue 35, 2013, Pages 3269-3274

  Kim, Ji Young ^a   Jeon, Beom Seok ^b   Kim, Han Joon ^b   Ahn, Tae Beom ^c  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

5 bromo 2 deoxyuridine; Alpha synuclein; Dopaminergic; Extracellular; Grants supported paper; Nanomolar; Neural regeneration; Neuronal differentiation; Neuronal survival; Neuroregeneration; Phosphorylated Akt; Proliferation; SH SY5Y cell

Indexed keywords

ALPHA SYNUCLEIN; PHOSPHOPROTEIN; PROTEIN KINASE B; BROXURIDINE;

ARTICLE; BRDU ASSAY; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MTT ASSAY; WESTERN BLOTTING; NERVE CELL DIFFERENTIATION; PROTEIN PHOSPHORYLATION;

EID: 84892698142     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.35.001     Document Type: Article

References (25)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259-272.
2. Spillantini MG, Crowther RA, Jakes R, et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95:6469-6473.
3. Burré J, Sharma M, Tsetsenis T, et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663-1667.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045-2047.
5. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106-108.
6. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164-173.
7. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167-1169.
8. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.
9. Lee SJ. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci. 2008;34:17-22.
10. Borghi R, Marchese R, Negro A, et al. Full length al-pha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett. 2000;287:65-67.
11. El-Agnaf OM, Irvine GB. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans. 2002;30:559-565.
12. Du HN, Tang L, Luo XY, et al. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry. 2003;42:8870-8878.
13. Luk KC, Song C, O'Brien P, et al. Exogenous alphasynuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051-20056.
14. Bae EJ, Lee HJ, Rockenstein E,et al. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32(39):13454-69.
15. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005;46:857-868.
16. Park SM, Kim KS. Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease. Prion. 2012;7. In press.
17. Seo JH, Rah JC, Choi SH, et al. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt pathway. FASEB J. 2002;16:1826-1828.
18. Manning-Bog AB, McCormack AL, Purisai MG, et al. Alpha-synuclein overexpression protects against paraquatinduced neurodegeneration. J Neurosci. 2003;23:3095-3099.
19. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci. 2006;26:7502-7512.
20. Choong CJ, Say YH. Alpha-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K. Neurotoxicology. 2011;32:857-863.
21. Nakaso K, Ito S, Nakashima K, et al. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci Lett. 2008;432:146-150.
22. Qin R, Li X, Li G, et al. Protection by tetrahydroxystilbene glucoside against neurotoxicity induced by MPP+: the involvement of PI3K/Akt pathway activation. Toxicol Lett. 2011;202:1-7.
23. Thomas B, Mandir AS, West N, et al. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PLoS One. 2011;6:e16706.
24. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338
25. Beyer K, Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol. in press.